3,600 Shares in Insulet Corporation $PODD Purchased by New England Research & Management Inc.

New England Research & Management Inc. acquired a new position in Insulet Corporation (NASDAQ:PODD) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 3,600 shares of the medical instruments supplier’s stock, valued at approximately $1,023,000.

Other large investors have also bought and sold shares of the company. True Wealth Design LLC raised its position in shares of Insulet by 288.0% in the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 72 shares in the last quarter. Whittier Trust Co. of Nevada Inc. lifted its stake in shares of Insulet by 48.9% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 43 shares during the period. Measured Wealth Private Client Group LLC bought a new stake in shares of Insulet during the third quarter valued at approximately $49,000. Quent Capital LLC bought a new stake in shares of Insulet during the third quarter valued at approximately $49,000. Finally, Osterweis Capital Management Inc. purchased a new stake in Insulet in the second quarter worth $51,000.

Insulet Stock Down 0.7%

Shares of NASDAQ:PODD opened at $227.10 on Friday. The stock has a fifty day simple moving average of $252.11 and a two-hundred day simple moving average of $293.18. The stock has a market capitalization of $15.99 billion, a price-to-earnings ratio of 64.89, a PEG ratio of 1.36 and a beta of 1.42. Insulet Corporation has a 12-month low of $216.49 and a 12-month high of $354.88. The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The firm had revenue of $783.80 million for the quarter, compared to analysts’ expectations of $768.31 million. During the same period in the prior year, the firm posted $1.15 earnings per share. The company’s quarterly revenue was up 31.2% on a year-over-year basis. On average, research analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Leerink Partners decreased their price objective on Insulet from $386.00 to $360.00 and set an “outperform” rating for the company in a report on Thursday, February 19th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Insulet in a research report on Thursday, January 22nd. Zacks Research lowered shares of Insulet from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 5th. JPMorgan Chase & Co. lowered their price target on shares of Insulet from $415.00 to $340.00 and set an “overweight” rating for the company in a research report on Thursday, February 19th. Finally, Evercore set a $340.00 price objective on shares of Insulet in a research note on Thursday, February 19th. Twenty equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Insulet presently has an average rating of “Moderate Buy” and an average target price of $354.24.

Insider Transactions at Insulet

In other news, Director Michael R. Minogue purchased 2,030 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were bought at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the purchase, the director directly owned 17,483 shares in the company, valued at approximately $4,304,839.09. This trade represents a 13.14% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.39% of the stock is currently owned by insiders.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.